Hanmi Pharm, Stock Price -2.95% at This Hour... 132,760 Shares Net Bought by Individuals in Last 5 Days

Hanmi Pharm is trading at 345,000 KRW as of 11:30 AM on the 7th, down 2.95% from the previous day. The trading volume is 408,464 shares, which is about 14.57% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.

On August 5th, Seogeunhee, a researcher at Samsung Securities, stated, "The stock price has been strong recently due to 1) positive clinical trial results announced for Pozitotinib Cohort 2 and 2) the possibility of corporate governance restructuring. Although an increase in R&D expenses is inevitable following the final contract termination with Sanofi for Efpeglenatide at the end of September, additional momentum remains valid with the FDA approval application for Oracsol in 2H20, FDA approval for Rolontis, and expectations for technology transfer of HM15211 (Triple agonist), which is scheduled to start Phase 2 clinical trials." He set the target price for Hanmi Pharm at 320,000 KRW.

Over the past five days, individual investors have net purchased 130,276 shares of Hanmi Pharm, while foreign investors and institutions have net purchased 7,439 shares and net sold 116,641 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.